Hoʻopili ʻia ko mākou olakino e nā kumu he nui.ʻAʻole hiki i nā mea kūʻai ke hoʻopili koke i ke olakino noʻonoʻo me ko lākou olakino holoʻokoʻa, akā pili nui ke olakino cognitive, kino a me ka naʻau.Hōʻike ʻia kēia ma ke ʻano e hiki ai i nā hemahema meaʻai ke hoʻemi i ka hana naʻau (e laʻa, B12 a me ka magnesium).
ʻIke ʻia nō hoʻi i ko mākou mau makahiki.ʻOi aku ka ʻelemakule, ʻoi aku ka liʻiliʻi o nā meaʻai e hiki ai i ke kino ke hoʻomoʻa mai ka meaʻai, ʻo ia ka hopena i nā hemahema.He mea maʻalahi ka hoʻokuʻu ʻana i ka poina a me ka nele o ka nānā ʻana e like me nā hōʻailona o ka makahiki, ʻo ia hoʻi, akā he hōʻailona hoʻi ia o ke kūlana holoʻokoʻa o ko mākou kino ma muli o ka ʻelemakule.ʻO ka hoʻohui ʻana, ma ka hana ʻana i nā hemahema o nā meaʻai, hiki ke hoʻomaikaʻi i ka hana cognitive.Eia kekahi mau meaʻai kikoʻī e pili ana i ke olakino cognitive.
Hoʻokahi hapakolu o ka lolo he polyunsaturated fatty acids (PUFA), he 15-30% o ke kaumaha maloʻo o ka lolo, me ka docosahexaenoic acid (DHA) e hana ana ma kahi o ka hapakolu o ia (1).
ʻO DHA kahi momona momona omega-3 e hana koʻikoʻi i ka lolo, e kau ana i nā ʻāpana o ka lolo e koi ai i ke kiʻekiʻe kiʻekiʻe o ka hana uila, me nā synaptosomes kahi e hui ai nā hopena nerve a kamaʻilio pū kekahi me kekahi, mitochondria, ka mea e hoʻoulu ai i ka ikehu no nā pūnana aʻalolo, a me ka ʻāʻī o ka lolo, ʻo ia ka papa waho o ka lolo (2).He mea koʻikoʻi ka DHA no ka ulu ʻana o ka lolo pēpē a me ke keiki a he mea koʻikoʻi ia i ke ola a pau no ka mālama ʻana i ke olakino cognitive kūpono.ʻIke ʻia ke koʻikoʻi o ka DHA i ko kākou mau makahiki i ka wā e nānā ai i ka poʻe i hoʻopilikia ʻia e ka emi ʻana o ka makahiki, e like me ka maʻi o Alzheimer (he ʻano dementia e hoʻoulu ai i ka hoʻomanaʻo holomua, ka noʻonoʻo a me ka emi ʻana o ke ʻano).
Wahi a ka loiloi a Thomas et al., "I nā poʻe maʻi i ʻike ʻia me ka maʻi o Alzheimer, ʻike ʻia nā pae DHA haʻahaʻa haʻahaʻa i ka plasma koko a me ka lolo.ʻAʻole wale kēia ma muli o ka haʻahaʻa haʻahaʻa o ka meaʻai o ka omega-3 fatty acids, akā hiki ke hoʻopili ʻia i ka hoʻonui ʻia ʻana o nā PUFA "(3).
I nā poʻe maʻi o Alzheimer, manaʻo ʻia ka emi ʻana o ka naʻau ma muli o ka protein beta-amyloid, kahi mea ʻona i nā pūnana nerve.Ke piʻi aʻe nā pae o kēia protein, hoʻopau lākou i nā ʻāpana nui o nā sela lolo, e waiho ana ma hope o nā pā amyloid e pili ana i ka maʻi (2).
Ua hōʻike ʻia nā haʻawina like ʻole e hiki i ka DHA ke loaʻa i kahi hopena neuroprotective ma o ka hoʻemi ʻana i ka beta-amyloid toxicity a me ka hāʻawi ʻana i kahi hopena anti-inflammatory e hiki ai ke hōʻemi i ke koʻikoʻi oxidative i hoʻokumu ʻia e ka amyloid plaque a hoʻemi i nā pae o nā protein oxidized e 57% (2).ʻOiai he hemahema ka DHA i ka poʻe maʻi o Alzheimer e pili ana i ke ʻano e hiki ai i ka supplementation ke pōmaikaʻi iā lākou, pono e hoʻomaopopo ʻia ʻaʻole hiki i nā mea hoʻohui ke hoʻōla i kēia a i ʻole kekahi maʻi a me nā haʻawina e pili ana i kēlā kumuhana i loaʻa nā hopena like ʻole.
ʻAʻole lāʻau lapaʻau nā mea hoʻohui, a ʻo ka mea ʻoiaʻiʻo ʻo nā maʻi o Alzheimer i ʻoi aku ka nui o ka makahiki e pōmaikaʻi ka liʻiliʻi loa mai DHA a i ʻole nā meaʻai ʻē aʻe no ke kākoʻo cognitive no ka mea ma ka manawa i ʻike ʻia ai, ua hana ʻia ka pōʻino kino i ka lolo.
Eia nō naʻe, ke noiʻi nei kekahi poʻe noiʻi inā hiki i ka hoʻohui DHA ke hoʻolōʻihi i ka holomua o ka emi ʻana o ka cognitive.ʻO Itay Shafat Ph.D., ʻepekema kiʻekiʻe no ka māhele meaʻai ma Enzymotec, Ltd., me ke keʻena US ma Morristown, NJ, haʻi i kahi noiʻi a Yourko-Mauro et al.i loaʻa, "Supplementation o 900 mg / lā DHA no 24 pule, i nā kumuhana makahiki> 55 me ka haʻahaʻa cognitive emi, hoʻomaikaʻi i ko lakou hoomanao a me ke aʻo akamai" (4).
ʻOiai ʻaʻole noʻonoʻo kekahi mau mea kūʻai e pili ana i ke olakino cognitive a hiki i ka wā e kū mai ai nā pilikia, he mea nui ia no nā mea kūʻai aku e hoʻomanaʻo iā lākou i ke koʻikoʻi o DHA no ka lolo i ke ola holoʻokoʻa.ʻO ka ʻoiaʻiʻo, hiki i ka DHA ke kākoʻo i ke olakino noʻonoʻo o ka poʻe ʻōpio i olakino a ʻaʻohe hemahema o nā meaʻai.Ua ʻike ʻia kahi hoʻāʻo i hoʻopaʻa ʻia e Stonehouse et al., e aʻo ana i 176 mau mākua olakino mai 18 a hiki i 45, "Ua hoʻomaikaʻi nui ka DHA supplementation i ka manawa pane o ka hoʻomanaʻo episodic, akā ua hoʻomaikaʻi ʻia ka pololei o ka hoʻomanaʻo episodic i nā wahine, a me ka manawa pane o Ua hoʻomaikaʻi ʻia ka hoʻomanaʻo hana i nā kāne" (5).ʻO kēia hoʻomaikaʻi ʻana i ka wā ʻōpio hiki ke unuhi i loko o ke kino a me ka noʻonoʻo i mākaukau maikaʻi ʻia no nā pilikia o ka wā ʻelemakule.
ʻO ka alpha-linolenic acid (ALA) he omega-3, i loaʻa pinepine ʻia mai nā mea kanu e like me ka chia a me ka flaxseed ma ke ʻano he koho i nā aila kai.He mea mua ka ALA i ka DHA, akā ʻaʻole kūpono ka hoʻololi ʻana i nā ʻanuʻu he nui mai ALA a i DHA i nā poʻe he nui, no laila e lilo ai ka DHA meaʻai i mea koʻikoʻi no ke kākoʻo naʻau.He mau hana ko'iko'i 'ē a'e 'o ALA ma kona 'ano pono'ī.Ua ʻōlelo ʻo Herb Joiner-Bey, ka mea aʻoaʻo ʻepekema lapaʻau no Barlean's, Ferndale, WA, ʻo ALA kekahi, "hoʻohana ʻia e nā ʻili o ka lolo e hana i nā hormones kūloko, me nā 'neuroprotectins,' koʻikoʻi i ka hana o ka lolo."Ua ʻōlelo ʻo ia he haʻahaʻa ka neuroprotectins i nā maʻi o Alzheimer a ma nā hoʻokolohua hoʻokolohua, ua manaʻo ʻia ʻo ALA he mea nui i ka ulu ʻana o ka lolo.
ʻO nā kumu e noʻonoʻo ai i ka lawe ʻana i nā mea hoʻohui DHA ʻo ia ka dosage a me ka bioavailability.ʻAʻole lawa ka DHA i ka poʻe he nui i kā lākou meaʻai a e pōmaikaʻi lākou i ka lawe ʻana i nā mea hoʻohālikelike kiʻekiʻe.Ua hōʻike ʻia ke koʻikoʻi o ka dosage i kahi haʻawina ʻelima makahiki e Chew et al.ʻaʻole i loaʻa ka ʻokoʻa koʻikoʻi i ka hana cognitive i ka wā o ka hoʻohui ʻana o omega-3 i nā poʻe ʻelemakule (mean makahiki: 72) me ka degeneration macular pili i ka makahiki.Nui ka poʻe akamai i ka meaʻai i kanalua i ka hoʻolālā haʻawina.No ka laʻana, ua ʻōlelo ʻo Jay Levy, ka luna kūʻai no Wakunaga o America Co., Ltd., Mission Viejo, CA, "ʻO ka mea DHA he 350 mg wale nō ʻoiai ua ʻike ʻia ka meta-analysis hou i kēlā me kēia lā DHA ma luna o 580 mg e pono ai. hāʻawi i nā pono hana cognitive" (6).
Ua haʻi ʻo Douglas Bibus, Ph.D., he lālā aʻoaʻo ʻepekema no Coromega, Vista, CA, i kahi ʻatikala a ka Global Organization for EPA a me DHA Omega-3s (GOED) i kapa ʻia "Omega-3s and Cognition: Dosage Matters."Ua ʻike ka hui, ma hope o ka "noʻonoʻo ʻana i nā haʻawina cognitive-based 20 i hana ʻia i loko o nā makahiki he 10 i hala iho nei, ʻo nā haʻawina e hāʻawi ana i ka 700 mg o DHA a ʻoi aku paha i kēlā me kēia lā i hōʻike i nā hopena maikaʻi" (7).
Hiki i kekahi mau palapala hoʻouna ke hoʻomoe i ka ʻaila kai.No ka laʻana, ʻōlelo ʻo Andrew Aussie, ka pelekikena hoʻokō a me ka luna hoʻokele nui ma Coromega, ʻo kāna ʻoihana loea i ka, "emulsified omega-3 supplements e hāʻawi ana i ka 300% maikaʻi loa o ka absorption."Wahi a ka haʻawina a Raatz et al.ʻO Aussie i ʻōlelo ai, ʻo ka emulsification lipid i loko o ka ʻōpū he mea koʻikoʻi ia i ka hoʻoheheʻe ʻana i ka momona "ma o ka hana ʻana o kahi lipid-wai interface pono no ka pilina ma waena o nā lipases hiki ke hoʻoheheʻe ʻia a me nā lipid insoluble" (8).No laila, ma ka emulsifying i ka ʻaila iʻa, ua kaʻe ʻia kēia kaʻina hana, e hoʻonui ai i kona hiki ke komo (8).
ʻO kahi kumu ʻē aʻe e pili ana i ka bioavailability ʻo ke ʻano molekala o omega-3.ʻO Chris Oswald, DC, CNS, he lālā o ka papa aʻoaʻo ma Nordic Naturals, Watsonville, CA, manaʻoʻiʻo ʻoi aku ka maikaʻi o ke ʻano triglyceride o omega-3s i ka hoʻonui ʻana i nā pae serum koko ma mua o nā ʻano synthetic.Ke hoʻohālikelike ʻia me nā molekele ethyl ester synthetic, ʻoi aku ka liʻiliʻi o ke ʻano triglyceride kūlohelohe i ka digestion enzymatic, a hiki i ka 300% ʻoi aku ka hiki ke komo (2).Ma muli o kona ʻano mole o ʻekolu mau momona momona i hoʻopili ʻia i ka iwi kuamoʻo glycerol, i ka wā e ʻeli ʻia ai ka aila iʻa, e hoʻololi ʻia ko lākou ʻano lipid i mau ʻakika momona hoʻokahi.Ma hope o ka hoʻopili ʻia ʻana i loko o nā cell epithelial, hoʻohuli hou ʻia lākou i triglycerides.Hiki kēia ma muli o ka iwi kuamoʻo glycerol i loaʻa, ʻaʻole i loaʻa i ka ethyl ester (2).
Manaʻo nā hui ʻē aʻe i ka phospholipid-bound omega-3 e hoʻomaikaʻi i ka absorption.Ua ʻōlelo ʻo Cheryl Meyers, ke poʻo o ka hoʻonaʻauao a me nā ʻoihana ʻepekema ma EuroPharma, Inc., Greenbay, WI, ʻo kēia ʻano hana "ʻaʻole wale ka hana ʻana ma ke ʻano he kaʻa lawe no nā omega-3s, akā hāʻawi pū kekahi i ke kākoʻo lolo ikaika iā lākou iho."Ua wehewehe ʻo Myers i hoʻokahi mea hoʻohui mai kāna hui e hāʻawi ana i ka phospholipid-bound omega-3 i unuhi ʻia mai nā poʻo salmon (Vectomega).Loaʻa i ka waihona i nā peptides āna i manaʻoʻiʻo ai "hiki ke pale i nā kīʻaha koko palupalu i loko o ka lolo ma ka hakakā ʻana i ka pōʻino oxidative."
No nā kumu like, koho kekahi mau ʻoihana e hana me ka ʻaila krill, kahi kumu ʻē aʻe o ka phospholipid-bound omega-3s e hāʻawi ana i ka bioavailability maikaʻi ma muli o ko lākou hiki ʻana i ka wai.Ua hāʻawi ʻo Lena Burri, ka luna kākau ʻepekema ma Aker Biomarine Antarctic AS, Oslo, Norewai, i kahi wehewehe hou no ke kumu he mea nui loa kēia ʻano DHA: hoʻokahi "DHA transporter (Mfsd2a, major facilitator super family domain i loaʻa 2a)… ua hoʻopaʻa ʻia i nā phospholipids—e like me ka lysoPC" (9).
Hoʻokahi haʻawina hoʻohālikelike i hoʻohālikelike ʻia, pālua-makapō, hui like i nā hopena o ka aila krill, ka aila sardine (triglyceride form) a me ka placebo ma ka hana hoʻomanaʻo a me ka helu ʻana i nā hana ma 45 mau kāne kahiko mai 61-72 no 12 pule.Ma ke ana ʻana i nā loli o ka oxyhemoglobin i ka wā o nā hana, ua hōʻike nā hopena i nā loli ʻoi aku ka nui o ka neʻe ʻana ma kahi kahawai ma hope o nā pule he 12 ma mua o ka placebo, e hōʻike ana i ka hoʻohui lōʻihi o ka ʻaila krill a me ka sardine "hoʻoikaika i ka hana hoʻomanaʻo hana ma ka hoʻoulu ʻana i ka dorsolateral prefrontal cortex i nā ʻelemakule. kanaka, a pēlā e pale ai i ka hoʻohaʻahaʻa ʻana i ka hana cognitive"(10).
Eia naʻe, e pili ana i nā hana helu, ua hōʻike ka ʻaila krill "i nā loli nui loa i ka nui o ka oxyhemoglobin ma ka ʻaoʻao hema hema," i hoʻohālikelike ʻia me kahi placebo a me ka aila sardine, ʻaʻole i hōʻike i nā hopena hoʻāla i ka wā o nā hana helu (10).
Ma waho aʻe o ke kōkua ʻana i ka absorption o omega-3s, he mea nui ka phospholipids i ke olakino cognitive i ko lākou pono ponoʻī.Wahi a Burri, ʻo ka phospholipids e pili ana i ka 60% o ka lolo ma ke kaupaona, ʻoi aku ka waiwai i nā dendrites a me nā synapses.Ma waho aʻe o kēia, ʻōlelo ʻo ia i ka in vitro, ulu ka nerve e hoʻonui i ka koi no ka phospholipids a me ka mea ulu nerve e hoʻoulu ai i ka hanauna phospholipid.Hoʻohana nui ʻia ka hoʻohui ʻana me nā phospholipids i ke kōkua ʻana i ka hana cognitive no ka mea ua like ko lākou ʻano me nā mea i loko o nā membrane nerve.
ʻElua mau phospholipid maʻamau he phosphatidylserine (PS) a me ka phosphatidylcholine (PC).Ua ʻōlelo ʻo Shafat ua loaʻa iā PS nā koi olakino kūpono i ʻae ʻia e ka US Food and Drug Administration (FDA).ʻO nā ʻōlelo hoʻopiʻi penei: "Hiki i ka hoʻohana ʻana i ka PS ke hōʻemi i ka hopena o ka dementia i ka poʻe ʻelemakule," "Hiki i ka hoʻohana ʻana i ka PS ke hōʻemi i ka pilikia o ka cognitive dysfunction i ka poʻe ʻelemakule," a kūpono me, "Ua kaupalena ʻia a me ka noiʻi ʻepekema mua e hōʻike ana e hōʻemi paha ka PS i ka pilikia. o ka dementia / hoemi i ka pilikia o ka cognitive dysfunction i ka poe elemakule.Hoʻopau ka FDA he liʻiliʻi nā hōʻike ʻepekema e kākoʻo ana i kēia ʻōlelo.
Ua wehewehe ʻo Shafat iā ia iho, "ua ikaika ʻo PS ma kahi o 100 mg / lā," ʻoi aku ka liʻiliʻi ma mua o kekahi mau mea kākoʻo cognitive.
E like me kāna hana, ʻo Chase Hagerman, ka luna hōʻailona ma ChemiNutra, White Bear Lake, MN, i ʻōlelo ʻo PS "kōkua i nā protein e hoʻokele i nā hana membrane e pili ana i ka hoʻouna ʻana i nā memo mole mai ke cell a cell, kōkua i nā meaʻai e komo i loko o nā cell, a kōkua. ʻino nā huahana ʻōpala pili i ke koʻikoʻi e puka i waho o ke kelepona."
ʻO ka PC, ma ka ʻaoʻao ʻē aʻe, e like me ka mea i hana ʻia mai ka alpha-glyceryl phosphoryl choline (A-GPC), ʻōlelo ʻo Hagerman, "e neʻe ana i nā hopena nerve synaptic i loaʻa i loko o ka ʻōnaehana nerve waena, a hoʻonui i ka synthesis a me ka hoʻokuʻu acetylcholine (AC)," he mea neurotransmitter koʻikoʻi ia "i loko o ka lolo a me ka ʻiʻo o ka ʻiʻo," e pāʻani ana i kahi kuleana nui i "ke kumu o kēlā me kēia hana cognitive i loko o ka ʻiʻo he mea nui ia i ka ʻoki ʻana i ka ʻiʻo."
Hana nā ʻano mea like ʻole i kēia hopena.ʻO Dallas Clouatre, Ph.D., ka mea aʻoaʻo R&D ma Jarrow Formulas, Inc., Los Angeles, CA, wehewehe iā lākou he "ʻohana lōʻihi o hoʻokahi substrate," ʻo ia hoʻi ka uridine, choline, CDP-choline (Citocoline) a me PC ʻāpana o ka pōʻai lolo i kapa ʻia ʻo Kennedy Cycle.Ke hana nei kēia mau mea a pau i ka hana ʻana i ka PC ma ka lolo a pēlā e synthesizing AC.
ʻO ka hana AC kekahi mea e emi iho ana i ko mākou mau makahiki.Eia nō naʻe, ma ke ʻano laulā, no ka mea ʻaʻole hiki i nā neurons ke hana i kā lākou koho ponoʻī a pono e loaʻa mai ke koko, nā meaʻai hemahema-choline e hana i kahi lako ʻole o AC (2).ʻO ka nele o ka choline i loaʻa ke kuleana i ka ulu ʻana o nā maʻi e like me ka Alzheimer a me ka emi ʻana o ka cognitive pili i ka makahiki.ʻO ka hana a ka mea noiʻi ʻo Richard Wurtman, MD, mai Massachusetts Institute of Technology ua manaʻo ʻia ma muli o ka lawa ʻole o ka choline, hiki i ka lolo ke ʻai maoli i ka PC mai kāna membrane neural ponoʻī e hana AC (2).
Ua wehewehe ʻo Neil E. Levin, CCN, DANLA, ka luna hoʻonaʻauao meaʻai ma NOW Foods, Bloomingdale, IL i kahi hoʻolālā "e kākoʻo ana i ka makaʻala noʻonoʻo a me ke aʻo ʻana ma o ka hoʻoikaika ʻana i ka hana a me ka hana AC kūpono," ma ka hoʻohui ʻana i ka A-GPC, "ke ʻano bioavailable o choline. , "me Huperzine A e mālama i nā pae AC (RememBRAIN mai NOW Foods).Mālama ʻo Huperzine A i ka AC ma ka hana ʻana ma ke ʻano he mea hoʻopale koho o ka acetylcholinesterase, ʻo ia ka enzyme e hoʻopau ai i ka AC (11).
Wahi a Levy, ʻo citicoline kekahi o nā mea hou aʻe no ke kākoʻo ʻana i ka cognition, e kuhikuhi ana i ka lobe frontal, ʻo ia ke kuleana no ka hoʻoponopono pilikia, ka nānā ʻana a me ka noʻonoʻo.Ua ʻōlelo ʻo ia ʻo ka hoʻohui ʻana me ka citicoline i ka poʻe ʻelemakule ua hōʻike i ka "hoʻomaikaʻi i ka hoʻomanaʻo waha, ka hana hoʻomanaʻo a me ka cognition, ka lōʻihi o ka nānā ʻana, ke kahe koko i ka lolo a me ka hana bioelectrical."Ua haʻi ʻo ia i kekahi mau haʻawina i hōʻike i nā hopena maikaʻi, me ka hoʻāʻo ʻelua makapō, randomized, placebo-controlled trial o 30 Alzheimer's maʻi i hōʻike i ka hoʻomaikaʻi ʻana i ka hana cognitive i hoʻohālikelike ʻia me ka placebo ma hope o ka lawe ʻana i ka citicoline i kēlā me kēia lā, ʻoi aku hoʻi i waena o ka poʻe me ka dementia haʻahaʻa (12).
Ua ʻōlelo ʻo Elyse Lovett, ka luna kūʻai kūʻai ma Kyowa USA, Inc., New York, NY, ʻo kāna hui "he ʻano citicoline wale nō i aʻo ʻia i ke kino i nā pākeke olakino a me nā ʻōpio," a ʻo ia "ke ʻano o ka citicoline me GRAS [maʻamau. ʻike ʻia he kūlana palekana] ma ʻAmelika Hui Pū ʻIa” (Cognizin).
ʻO kekahi mea hoʻohui e pili ana, e like me Dan Lifton, pelekikena o Maypro's Proprietary Branded Ingredients Group, Purchase, NY, ʻo INM-176 i loaʻa mai ke kumu Angelica gigas Nakai, i hōʻike ʻia e kākoʻo i ke olakino cognitive ma o ka hoʻonui ʻana i ka pae o ka lolo o AC.
Hōʻike pinepine ʻia nā hemahema o ka vitamina ma o ka emi ʻana o ka hana cognitive.ʻO ka nele o ka Vitamin B12, no ka laʻana, hiki ke komo i nā hōʻailona e like me ka huikau, ka nalowale o ka hoʻomanaʻo, nā loli o ke ʻano, ka paranoia, ke kaumaha a me nā ʻano ʻē aʻe e like me ka dementia.ʻAʻole ʻo ia wale nō, akā ʻo 15% o ka poʻe ʻelemakule a me ka nui o 40% o nā poʻe maʻi ma luna o 60 mau makahiki he haʻahaʻa a i ʻole nā palena palena B12 (13).
Wahi a Mohajeri et al., he kuleana koʻikoʻi ka B12 i ka hoʻololi ʻana i ka homocysteine (Hcy) i loko o ka methionine amino acid, akā ʻo nā huaola B ʻē aʻe folate (B9) a me B6 he mau cofactors pono no ka hiki ʻana o ka metabolization, me ka ʻole o ia, e hōʻiliʻili ʻo Hcy.ʻO ka Hcy he amino acid i hana ʻia i loko o ke kino mai ka methionine meaʻai a he mea nui ia no ka hana kelepona maʻamau, akā ʻo ka nui o ia mea e hoʻohaʻahaʻa i ka hana ʻana (14)."Ua hōʻike ʻia ke kiʻekiʻe o ke koko kiʻekiʻe o ka homocysteine e hoʻololi i ka hoʻomanaʻo a me nā ʻano ʻē aʻe o ka hana cognitive," wahi a Michael Mooney, ka luna o ka ʻepekema a me ka hoʻonaʻauao ma SuperNutrition, Oakland, CA.
Mohajeri et al.E kākoʻo ana i kēia ʻōlelo: "Ua pili ka paʻakikī o ka hōʻino cognitive me ka hoʻonui ʻia o ka plasma Hcy.Eia kekahi, ʻoi aku ka nui o ka pilikia o ka maʻi o Alzheimer i ka wā i haʻahaʻa ai nā pae folate a me B12" (15).
ʻO Niacin kekahi huaʻai B e kākoʻo i ka hoʻomanaʻo a me ka hana cognitive.Wahi a Mooney, ʻo ka niacin, ke ʻano ikaika o ka huaora B3, kuhikuhi pinepine ʻia e nā kauka ma 1,000 mg a ʻoi aku paha i kēlā me kēia lā e kākoʻo i nā pae cholesterol maʻamau, akā ua ʻike ʻia kahi haʻawina i hoʻopaʻa ʻia e kahi placebo e hoʻomaikaʻi i ka hoʻomanaʻo ʻana o ka meaʻai o 425 mg i kēlā me kēia lā. nā helu hōʻike e like me ka 40% a me ka hoʻomaikaʻi ʻana i ke kākau inoa sensory e like me 40%.I nā potencies kiʻekiʻe, hōʻike ʻia ka niacin e hoʻomaikaʻi i ke kahe o ke koko cerebral, "e hoʻonui ai i ke kahe o nā meaʻai a me ka oxygen i loko o ka lolo," hoʻohui ʻo ia (16).
Ma kahi o ka niacin, ua wehewehe ʻo Mooney i ka niacinamide, ʻo ia kekahi ʻano o ka huaora B3.Ma ka 3,000 mg / lā, ke aʻo ʻia nei ka niacinamide e UC Irvine ma ke ʻano he lāʻau lapaʻau no ka Alzheimer a me ka nalowale hoʻomanaʻo e pili ana me ia ma hope o nā hopena maikaʻi i ka noiʻi ʻiole.ʻO nā ʻano ʻelua, wehewehe ʻo ia, e hoʻololi i loko o ke kino i NAD +, kahi mole i hōʻike ʻia e hoʻohuli i ka ʻelemakule i ka mitochondria, ka mea hana nui o ka ikehu cellular."He mea koʻikoʻi paha kēia i ka hoʻonui ʻana i ka hoʻomanaʻo o ka vitamin B3 a me nā hopena anti-aging ʻē aʻe," wahi āna.
ʻO kekahi mea hoʻohui e ʻōlelo aku i nā mea kūʻai aku ʻo PQQ.Wahi a Clouatre, ua manaʻo ʻia e kekahi ʻo ia wale nō ka huaora hou i ʻike ʻia i nā makahiki he nui i hala, e hōʻike ana i nā hopena maikaʻi ma nā wahi e like me ka neuroprotection."PQQ hoʻopaʻa i ka excessive hanauna o ka helu o radicals, me ka ino loa peroxynitrite radical," wahi ana, a ma PQQ ua hōʻike i ka hopena maikaʻi i ke aʻo a me ka hoʻomanaʻo i ka holoholona a me ke kanaka noiʻi.Ua ʻike kekahi hoʻokolohua lapaʻau i ka hui pū ʻana o 20 mg o PQQ a me CoQ10 i hāʻawi i nā pōmaikaʻi nui i nā kumuhana kanaka i ka hoʻomanaʻo, ka nānā ʻana a me ka cognition (17).
Wahi a Lifton e like me ka niacin, PQQ a me CoQ10 kākoʻo i ka hana mitochondrial.Ua ʻōlelo ʻo ia e hana ana ʻo CoQ10 ma ka pale ʻana i ka "mitochondria mai ka pōʻino ma muli o ka hoʻomau ʻana o ka free-radical onslaughts," a me ka hoʻonui ʻana i ka "hoʻoulu ʻana i ka ikehu cellular, hiki ke loaʻa ka ikehu hou no nā kaʻina cognitive."He mea nui kēia no ka mea "ʻo ka noiʻi hoihoi hou e hōʻike ana ʻo kekahi o nā kumu nui o nā pilikia hoʻomanaʻo haʻahaʻa e pili ana i ka ʻelemakule e hōʻino i kā mākou mitochondria," wahi a Lifton.
He mineral koʻikoʻi ka Magnesium no ka mālama ʻana i ka hana cognitive maikaʻi, a i ʻole no ia mea, ka hana kino holoʻokoʻa.Wahi a Carolyn Dean, MD, ND, he lālā aʻoaʻo lāʻau lapaʻau o ka Nutritional Magnesium Association, "ʻO ka Magnesium wale nō ke koi ʻia ma 700-800 mau ʻōnaehana enzyme ʻokoʻa" a me ka "ATP (adenosine triphosphate) hana i ka pōʻai Krebs e pili ana i ka magnesium no ʻeono. o kona mau kapuai ewalu.
Ma ka ʻaoʻao noʻonoʻo, ʻōlelo ʻo Dean e hoʻopaʻa ka magnesium i ka neuro-inflammation ma muli o ka waiho ʻana o ka calcium a me nā metala koʻikoʻi ʻē aʻe i loko o nā pūnāwai o ka lolo a me ke kiaʻi ʻana i nā kahawai ion a me ka pale ʻana i nā metala kaumaha mai ke komo ʻana.Ua wehewehe ʻo ia i ka haʻahaʻa ʻana o ka magnesium, e holo wikiwiki ana ka calcium i loko a make ke kino.Hoʻohui ʻo Levin, "Ua hōʻike ka noiʻi hou he mea koʻikoʻi ia no ke olakino lolo maʻamau a me ka hana cognitive maʻamau ma o ka mālama ʻana i ka paʻa a me ka paʻa o nā synapses neuronal."
Ma kāna puke ʻo The Magnesium Miracle, wehewehe ʻo Dean e hiki i nā hemahema o ka magnesium ke hana i nā hōʻailona o ka dementia.He ʻoiaʻiʻo kēia i ko mākou mau makahiki, ʻoiai ke emi nei ka hiki o ke kino ke komo i ka magnesium mai kā mākou meaʻai a hiki ke keʻakeʻa ʻia e nā lāʻau lapaʻau maʻamau i ka poʻe ʻelemakule (18).No laila, hiki ke emi ka pae o ka magnesium i loko o ke koko no ka mea ʻaʻole hiki i ke kino ke komo i ka mineral, nā meaʻai maikaʻi ʻole a me nā lāʻau lapaʻau, e hana ana i ka nui o ka calcium a me ka glutamate (ʻoi aku ka nui o ka ʻai ʻana i ka meaʻai kiʻekiʻe i ka MSG), he kuleana ko lāua ʻelua e pāʻani ai. i loko o ka neural degeneration mau a me ka ulu ʻana o ka dementia (19).
ʻOiai he mea koʻikoʻi nā meaʻai no ka mālama ʻana i ka hana cognitive olakino, hiki i nā mea kōkua lāʻau ke hāʻawi i ke kākoʻo hou i nā ʻano hana like ʻole.Hiki ke hana ʻia ka emi ʻana o ka naʻau e pili ana i ka makahiki a me ka dementia ma nā ʻano like ʻole, me ka emi ʻana o ke kahe koko cerebral ʻo ia kekahi o nā mīkini ʻokoʻa loa.Hoʻohana ʻia kekahi mau mea kanu e kū i kēia kumu.Pono e hoʻomaopopo ʻia ʻo nā lāʻau lapaʻau e hoʻomaikaʻi ai i ke kahe ʻana o ke koko he mea pōʻino i nā mea kūʻai aku e lawe nei i ka lāʻau hoʻokahe koko e like me warfarin.
ʻO kahi hana nui o Gingko biloba ka hoʻonui ʻana i ke kahe koko cerebral, kahi mea nui i ka hoʻomohala ʻana o ka dementia inā hoʻomaka ʻia e ka maʻi Alzheimer a i ʻole ka maʻi cerebrovascular.Ua ʻōlelo ʻia hoʻi e hoʻihoʻi i ka hana mitochondrial impaired e hoʻomaikaʻi i ka hāʻawi ʻana i ka ikehu neuronal, hoʻonui i ka choline uptake i loko o ka hippocampus, kaohi ʻana i ka aggregation a me ka toxicity o ka protein b-amyloid a loaʻa nā hopena antioxidant (20, 21).
Ua haʻi ʻo Levy i kahi haʻawina hoʻokele ʻehā pule ma Neuroradiology i "hōʻike i ka piʻi ʻana o ʻehā a ʻehiku pakeneka o ke kahe koko cerebral ma kahi maʻamau o 120 mg i kēlā me kēia lā" o gingko (22).ʻO kahi haʻawina hoʻokaʻawale ʻokoʻa, placebo-controlled, double-blind study e hoʻoholo ana i ka pono a me ka palekana o ka gingko biloba i nā poʻe maʻi me ka haʻahaʻa haʻahaʻa o ka naʻau a me nā hōʻailona neuropsychiatric (NPS) e Gavrilova et al. ʻO ka hoʻomaikaʻi ʻana i ka NPS a me nā mana cognitive he mea nui a ʻoi aku ka nui o nā mea maʻi e lawe ana i ka 240 mg i kēlā me kēia lā o G. biloba extract EGb 761 ma mua o nā mea maʻi e lawe ana i kahi placebo "(23).
Ke hoʻāʻo ʻia nei ka maikaʻi o ka gingko biloba ma nā ʻano ʻē aʻe e like me ka maʻi maʻi hoʻopono deficit hyperactive (ADHD) i nā keiki.ʻO kahi haʻawina palena akā hoʻohiki e Sandersleben et al.Ua hōʻike ʻia ma hope o ka hoʻohui ʻana me ka gingko, "ua loaʻa nā hoʻomaikaʻi koʻikoʻi no ka loiloi ʻana o nā mākua i ka nānā ʻana o kā lākou mau keiki ... hyperactivity, impulsivity, a me ka nui o ka nui o ka hōʻailona hōʻailona ua hoʻemi nui ʻia," a, "hoʻomaikaʻi nui e pili ana i ka Prosocial Behavior" (24) .Ma muli o nā palena o ka noiʻi ʻana, e like me ka loaʻa ʻole o ka mana a i ʻole ka laʻana nui, ʻaʻohe hopena paʻa e hiki ke huki ʻia i kona pono, akā lana ka manaʻolana e paipai ʻia i nā hoʻokolohua hoʻāʻo ʻana i ka randomized.
ʻO kekahi lāʻau lapaʻau e like me ka Bacopa monniera, e like me Levy, kahi noiʻi holoholona hou i Phytotherapy Research hōʻike i ka "25% ka piʻi ʻana o ke kahe koko i ka lolo ma waena o nā holoholona e lawe ana i ka 60 mg o ka bacopa monniera i kēlā me kēia lā i hoʻohālikelike ʻia me ka piʻi ʻole o nā mea i hāʻawi ʻia i donepezil. ” (25).
Ua ʻōlelo ʻia he mau waiwai antioxidant.Wahi a Shaheen Majeed, ka luna kūʻai kūʻai o Sabinsa Corp., East Windsor, NJ, ʻo ka bacopa "inhibits lipid peroxidation a ma laila e pale ai i ka hōʻino ʻana i nā neuron cortical."Hoʻomaka ka lipid peroxidation i ka wā o ke koʻikoʻi oxidative e pili ana me kahi hemahema DHA, ʻo ia hoʻi, he hōʻailona o Alzheimer.
Ua ʻōlelo pū ʻo Mary Rove, ND, ka mea hoʻonaʻauao olakino ma Gaia Herb, Brevard, NC, i ka hoʻohui ʻana i kā lākou Gingko supplements me nā mea kanu e like me ka peppermint a me ka rosemary.Wahi a ia, kākoʻo ka peppermint i ka makaʻala a "ua hoʻomaikaʻi ʻia ka noiʻi ʻana i ka rosmaranic acid, kahi mea hana ikaika me nā waiwai antioxidant."Huli ʻo ia, ua hoʻohui ʻo ia, "he nui nā ʻikepili hou e paʻa i kēlā ʻōlelo ʻōlelo 'rosemary no ka hoʻomanaʻo.'"
ʻO Huperzine A, i ʻōlelo ʻia ma mua no kāna hana ma ke ʻano he acetylcholinesterase inhibitor, ua loaʻa mai ka lāʻau Kina Huperzia serrata.ʻO kona hiki ke pale i ka haʻihaʻi ʻana o ka acetylcholine ua like ia me nā lāʻau lapaʻau i ʻae ʻia e FDA i ʻae ʻia e mālama i nā hōʻailona o ka maʻi o Alzheimer me donepezil, galantamine a me rivastigmine, ʻo ia ka cholinesterase inhibitors (11).
He meta-analysis i alakaʻi ʻia e Yang et al.Ua hoʻopau ʻia, "He hopena maikaʻi ʻo Huperzine A i ka hoʻomaikaʻi ʻana i ka hana cognitive, ka hana ola i kēlā me kēia lā a me ka loiloi o ka honua i nā poʻe me ka maʻi o Alzheimer."Ua ʻōlelo aku lākou, pono e unuhi ʻia nā ʻike me ka akahele ma muli o ka maikaʻi ʻole o ke ʻano o nā hoʻokolohua i hoʻopili ʻia, a kāhea ʻia nā hoʻokolohua ʻoi aku ka paʻakikī (11).
ʻO nā antioxidants.ʻO ka hapa nui o nā mea hoʻohui i kūkākūkā ʻia he mau antioxidant capacities, e kōkua iā lākou e hoʻopōmaikaʻi iā lākou e kūʻē i nā hemahema cognitive, kahi e hoʻopili pinepine ai nā koʻikoʻi oxidative.Wahi a Meyers, "Ma kahi kokoke i nā maʻi āpau i loko o ka lolo, he mea nui ka mumū - hoʻololi ia i ke ʻano o ke ʻano o ka launa pū ʻana o nā cell me kekahi."ʻO ia ke kumu i piʻi nui ai ka kaulana a me ka noiʻi ʻana i ka curcumin, kahi mea i loaʻa mai ka turmeric, i hōʻike ʻia e hōʻemi i ka pōʻino inflammatory a me ka oxidative i ka lolo a kākoʻo i ke kī ʻana o nā neurons, wahi a Meyers.
I ka hihia o nā kūlana e like me Alzheimer's, hiki i ka curcumin ke hiki ke hoʻopau i ke kūkulu ʻana o ka beta-amyloid.ʻO kahi noiʻi a Zhang et al., nāna i hoʻāʻo i ka curcumin ma nā moʻomeheu cell a me nā neuron cortical cortical mua, ʻike ʻia ua hoʻemi ka lau nahele i nā pae beta-amyloid ma ka hoʻolōʻihi ʻana i ka maturation o amyloid-beta precursor protein (APP).Ua attenuated APP maturation ma ka manawa like hoʻonui i ka paʻa o ka oo APP a me ka hoemi 'ana o ka makua APP (26).
Pono ka noiʻi hou aʻe e hoʻomaopopo pono i ke ʻano o nā hopena curcumin i hiki ke loaʻa i ka cognition a pehea e hoʻomaikaʻi ai i nā hemahema cognitive.I kēia manawa, ke kākoʻo nei ka McCusker Alzheimer's Research Foundation i ka noiʻi ʻana e mālama ʻia ana ma ke Kulanui ʻo Edith Cowan ma Perth, Australia, e hoʻāʻo ai i ka pono o ka curcumin i nā poʻe maʻi me ka ʻehaʻeha o ka naʻau.E loiloi ana ka haʻawina he 12 mau mahina inā e mālama ka lāʻau i ka hana cognitive o nā maʻi.
ʻO kekahi antioxidant ikaika e kākoʻo ana i ka hana cognitive ʻo Pycnogenol (i hāʻawi ʻia e Horphag Research).Ma waho aʻe o ka ikaika nui e kūʻē i ka pōʻino oxidative, ua hōʻike ʻia ka lau nahele, i loaʻa mai ka ʻili paina moana Farani, e hoʻomaikaʻi i ke kahe koko, me ka microcirculation i loko o ka lolo a me ka hoʻonui ʻana i ka hana o ka nitric oxide, e hana ana ma ke ʻano he neurotransmitter. , hāʻawi paha i ka hoʻomanaʻo a me ka hiki ke aʻo (25).Ma hoʻokahi haʻawina ʻewalu pule, hāʻawi nā mea noiʻi i 53 mau haumāna mai ka 18 a hiki i ka 27 Pycnogenol a loiloi i kā lākou hana ma nā hoʻokolohua maoli.Ua hōʻike nā hualoaʻa ua hāʻule ka hui hoʻokolohua i nā hoʻokolohua liʻiliʻi ma mua o ka mana (ʻehiku vs. ʻeiwa) a hana i ka 7.6% maikaʻi ma mua o ka mana (27).WF
1. ʻO Joseph C. Maroon lāua ʻo Jeffrey Bost, ʻAila Iʻa: ʻO ka Anti-Inflammatory kūlohelohe.Basic Health Publications, Inc. Laguna Beach, Kaleponi.2006. 2. Michael A. Schmidt, Brian-Building Nutrition: Pehea ka hopena o nā momona ʻai a me nā ʻaila i ka noʻonoʻo, kino, a me ka naʻau naʻau, ʻekolu puke.ʻO Frog Books, Ltd. Berkeley, Kaleponi, 2007. 3. J. Thomas et al., "Omega-3 fatty ccids i ka pale mua ʻana i ka maʻi neurodegenerative inflammatory: Ke nānā aku nei i ka maʻi o Alzheimer."Hindawa Publishing Corporation, BioMed Research International, Volume 2015, Article ID 172801. 4. K. Yurko-Mauro et al., "Nā hopena maikaʻi o ka waikawa docosahexaenoic ma luna o ka cognition i ka emi ʻana o ka cognitive e pili ana i ka makahiki. "Alzheimers Dement.6(6): 456-64.2010. 5. W. Stonehouse et al., "Ua hoʻomaikaʻi ka hoʻonui ʻana o DHA i ka hoʻomanaʻo a me ka manawa pane i nā ʻōpio ʻōpio olakino: kahi hoʻāʻo hoʻokele randomized."Am J Clin Nutr.97: 1134-43.2013. 6. EY Chew et al., "Ka hopena o ka omega-3 fatty acids, lutein/zeaxanthin, a i ʻole nā meaʻai meaʻai ʻē aʻe ma ka hana cognitive: ka AREDS2 randomized clinical trial."JAMA.314(8): 791-801.2015. 7. Adam Ismail, "Omega-3s a me ka cognition: nā mea pili."http://www.goedomega3.com/index.php/blog/2015/08/omega-3s-and-cognition-dosage-matters.8. Susan K. Raatz et al., "Hoʻonui i ka absorption o omega-3 fatty acids mai emulsified i hoʻohālikelike ʻia me ka ʻaila iʻa i hoʻopili ʻia."J Am Diet Assoc.109(6).1076-1081.2009. 9. LN Nguyen et al., "He mea lawe ka Mfsd2a no ka waikawa momona omega-3 docosahexaenoic acid."http://www.nature.com/nature/journal/v509/n7501/full/nature13241.html. hana: kahi ho'āʻo i hoʻopaʻa ʻia i nā mea manawaleʻa olakino olakino.Clin Interv Aging.8: 1247-1257.2013. 11. Guoyan Yang et al., "Huperzine A no ka maʻi o Alzheimer: he loiloi ʻōnaehana a me ka meta-analysis o nā hoʻokolohua hoʻokolohua randomized."PLoS KEKAHI.8(9).2013. 12. XA.ʻO Alvarez et al."Ka noiʻi ʻelua makapō placebo me ka citicoline i ka poʻe maʻi maʻi o Alzheimer genotyped APOE: Nā hopena i ka hana cognitive, ka hana bioelectrical lolo a me ka cerebral perfusion."ʻO nā ala e ʻimi ai iā Exp Clin Pharmacol.21(9):633-44.1999. 13. Sally M. Pacholok a me Jeffrey J. Stuart.Hiki paha iā B12: He Epidemic of Misdiagnosis, Second Edition.Buke Keaukaha Quill.Fresno, CA.2011. 14. M. Hasan Mohajeri et.Mea ai.31: 261-75.2015. 15. SM.ʻO Loriaux et al."ʻO nā hopena o ka nicotinic acid a me ka xanthinol nicotinate i ka hoʻomanaʻo kanaka ma nā ʻano makahiki like ʻole.He haʻawina makapō pālua."Psychopharmacology (Berl).867 (4): 390-5.1985. 16. Steven Schreiber, "Ke aʻo palekana o Nicotinamide e mālama i ka maʻi o Alzheimer."https://clinicaltrials.gov/ct2/show/NCT00580931?term=nicotinamide+alzheimer%27s&rank=1.17. Koikeda T. et.al, "Pyrroloquinoline quinone disodium paʻakai i hoʻomaikaʻi i nā hana o ka lolo."Kūkākūkā Lapaʻau a me nā lāʻau hou.48 (5): 519. 2011. 18. Carolyn Dean, Ka Mana Mana Magnesium.Nā Buke Ballantine, New York, NY.2007. 19. Dehua Chui et al., "Magnesium in Alzheimer's disease."ʻO ka Magnesium i loko o ka Pūnaehana Nervous Central.Ke Kulanui o Adelaide Press.2011. 20. S. Gauthier a me S. Schlaefke, "Efficacy and tolerability of Gingko biloba extract Egb 761 in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials."Nā Hana Hoʻomaʻamaʻa i ka ʻelemakule.9: 2065-2077.2014. 21. T. Varteresian a me H. Lavretsky, "Nā huahana kūlohelohe a me nā mea hoʻohui no ke kaumaha geriatric a me nā maʻi cognitive: kahi loiloi o ka noiʻi.Curr Psychiatry Rep. 6 (8), 456. 2014. 22. A. Mashayekh, et al., "Nā hopena o Ginkgo biloba ma ke kahe koko cerebral i loiloi ʻia e ka quantitative MR perfusion imaging: pilot study."Neuroradiology.53(3):185-91.2011. 23. SI Gavrilova, et al., "Efficacy and safety of Gingko biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo controlled, double-blind, multicenter trial."Int J Geriatr Psychiatry.29:1087-1095.2014. 24. HU Sandersleben et al., "Gingko biloba extract EGb 761 i nā keiki me ADHD."Z. Kinder-Jugendpsychiatr.Psychother.42 (5): 337-347.2014. 25. N. Kamkaew, et al., "Hoʻonui ka Bacopa monnieri i ke koko cerebral i ka ʻiole indpenddent o ke koko."ʻO Phytother Res.27(1):135-8.2013. 26. C. Zhang, et al., "Hoʻemi ʻo Curcumin i nā pae peptide amyloid-beta ma o ka hoʻemi ʻana i ka maturation o ka protein precursor amyloid-beta."J Biol Chem.285(37): 28472-28480.2010. 27. Richard A. Passwater, ke alakaʻi o ka mea hoʻohana i ka Pynogenol Nature's Mea Hoʻohui Nui Loa.Nā Paipai Ola Ola, Ke kahakai ʻo Laguna, CA.2005. 28. R. Lurri, et al., "Hoʻonui ka Pynogenol supplementation i ka hana cognitive, nānā a me ka hana noʻonoʻo i nā haumāna."J Nūnūnaʻi ʻepekema.58(4): 239-48.2014.
Paʻi ʻia ma WholeFoods Magazine Ianuali 2016
ʻO WholeFoods Magazine kāu kumu waiwai hoʻokahi no nā ʻatikala olakino a me ka meaʻai o kēia manawa, e pili ana i ka nohona manuahi gluten a me nā nūhou meaʻai.
ʻO ke kumu o kā mākou ʻatikala olakino a me ka meaʻai meaʻai ʻo ia ka hoʻomaopopo ʻana i nā mea kūʻai aku a me nā mea kūʻai aku e pili ana i ka huahana kūlohelohe hou loa a me nā nūhou meaʻai meaʻai, i hiki iā lākou ke hoʻohana i nā manawa hou a hoʻomaikaʻi i kā lākou ʻoihana.Hāʻawi kā mākou puke i ka ʻike koʻikoʻi e pili ana i nā ʻano huahana hou a me nā ʻano huahana hou o ka ʻoihana, me ka ʻepekema ma hope o nā mea hoʻohui meaʻai nui.
Ka manawa hoʻouna: Jun-20-2019